Quotables
"Without question, the greatest invention in the history of mankind is beer. Oh, I grant you that the wheel was also a fine invention, but the wheel does not go nearly as well with pizza."
Dave Barry
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120108542 | SULFATED OCTASACCHARIDE AND ITS USE AS ANTITHROMBOTIC AGENT The instant invention relates to the octasaccharide of formula (I): in its acid form or in the form of any one of its pharmaceutically acceptable salts, and to its process of preparation. The oligosaccharide ... | 05/03/2012 |
| 20120108543 | SULFATED HEPTASACCHARIDE AND ITS USE AS AN ANTITHROMBOTIC AGENT The instant invention relates to the heptasaccharide of formula (I):
| 05/03/2012 |
| 20120108544 | ACYLATED DECASACCHARIDES AND THEIR USE AS ANTITHROMBOTIC AGENTS The instant invention relates to decasaccharides of formula (I):
| 05/03/2012 |
| 20120108541 | ACYLATED 1,6-ANHYDRO DECASACCHARIDE AND ITS USE AS AN ANTITHROMBOTIC AGENT The instant invention relates to the decasaccharide of formula (I), wherein Ac represents an acetyl group: in its acid form or in the form of any one of its pharmaceutically acceptable salts, and to its proce... | 05/03/2012 |
| 20120083465 | METHOD FOR BLOCKING LIGATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) A method and medicament is provided for treating and inhibiting interaction of the receptor for advanced glycation end-products (RAGE) and its ligands using a natural or synthetic sulfated polysaccharide, preferably a 2-O desulfated heparin. The medicament preferably is... | 04/05/2012 |
| 20120083466 | LIPID CONJUGATES IN THE TREATMENT OF ALLERGIC RHINITIS Provided herein are methods of treating, suppressing, inhibiting, or preventing allergic rhinitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oli... | 04/05/2012 |
| 20120070483 | Multi-Functional Biocompatible Coatings for Intravascular Devices A polymeric coating is adapted to substantially eliminate thrombus formation when in contact with blood. The polymeric coating includes a first polymeric layer and a second polymeric layer. Interposed between the first and second polymeric layers is a polymeric matrix l... | 03/22/2012 |
| 20120070471 | ADMINISTRATION OF ENOXOPARIN SODIUM TO PATIENTS 75 YEARS AND OLDER WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION Methods for treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older. The methods comprise administering a dose of less than 1 mg per kg body weight, about 0.75 mg per kg of body weight, or 0.75 mg per kg of body weight of enoxapar... | 03/22/2012 |
| 20120052055 | METHOD OF TREATING THROMBOCYTOPENIA Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further a... | 03/01/2012 |
| 20120046241 | DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL IMPAIRMENT This invention relates to a dose of 10 mg of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment.... | 02/23/2012 |
| 20120046230 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions... | 02/23/2012 |
| 20120022020 | PHARMACEUTICAL FORMS FOR THE RELEASE OF ACTIVE COMPOUNDS A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 μmol ammonium groups/mg pharmaceutical composition, the pro... | 01/26/2012 |
| 20120021989 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of th... | 01/26/2012 |
| 20120015904 | BIOMARKERS FOR DIAGNOSIS OF TRANSIENT ISCHEMIC ATTACKS The present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient ischemic attacks (TIA).... | 01/19/2012 |
| 20120014874 | PHOTOSENSITIZER-METAL NANOPARTICLE CHARGE COMPLEX AND COMPOSITION CONTAINING THE COMPLEX FOR PHOTODYNAMIC THERAPY OR DIAGNOSIS Provided are a photosensitizer-metal nanoparticle charge complex and a composition for photodynamic therapy or diagnosis containing the same. The complex includes a metal nanoparticle, a photosensitizer charged with a first charge, and a linker bound to the metal nanopa... | 01/19/2012 |
| 20110315583 | INTRAVASCULAR INDWELLING CATHETER LOCK SOLUTION CONTAINING WEAK ACID AND CONTAINER CONTAINING THE SAME A catheter lock solution which is a catheter lock preparation having a bacteriostatic property at physiological osmotic pressure without practically containing a bacteriostatic component such as a preservative, an antimicrobial agent, or an antibiotic and having high sa... | 12/29/2011 |
| 20110318351 | NOVEL METHODS OF CANCER DIAGNOSIS AND THERAPY TARGETED AGAINST A CANCER STEM LINE Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treat... | 12/29/2011 |
| 20110318425 | TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR, 10aR)- DELTA-8-TETRAHDRAOCANNABINOL-11-OIC ACIDS The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-Δ8-tetrahydrocannabinol-11-oic acids (hereinafter referred... | 12/29/2011 |
| 20110300150 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and composit... | 12/08/2011 |
| 20110301112 | FUSED RING THROMBIN RECEPTOR ANTAGONISTS Fused-ring, heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein
| |
| 20110288048 | PROMOTER FOR HARD TISSUE FORMATION The present invention provides an agent which induces acceleration of hard tissue formation, acceleration of cell differentiation and increase in cellular alkaline phosphatase activity, by directly acting on the cell. Specifically, it provides a hard tissue formation pr... | 11/24/2011 |
| 20110288047 | PROCESS FOR THE PURIFICATION OF HEPARAN SULFATE AND USE THEREOF IN COSMETOLOGICAL AND DERMATOLOGICAL PREPARATIONS The present invention relates to cosmetological and dermatological compositions comprising heparan sulfate. The invention further discloses a process for the purification of heparan sulfate for dermatological and cosmetological applications, which process comprises the ... | 11/24/2011 |
| 20110288046 | ANALYSIS OF SULFATED POLYSACCHRIDES The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitori... | 11/24/2011 |
| 20110286937 | SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOME The present invention provides a glycolipid-containing liposome. In such a glycolipid-containing liposome, the glycolipid includes a plant ceramide portion and a sugar chain portion. The present invention also provides a method of producing a glycolipid-containing lipos... | 11/24/2011 |
| 20110281820 | GLYCOSAMINOGLYCANS DERIVED FROM K5 POLYSACCHARIDE HAVING HIGH ANTICOAGULANT AND ANTITHROMBOTIC ACTIVITIES AND PROCESS FOR THEIR PREPARATION Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the... | 11/17/2011 |
| 20110274749 | METHODS AND COMPOSITIONS FOR TARGETING AGENTS INTO AND ACROSS THE BLOOD-BRAIN BARRIER AND OTHER ENDOTHELIAL CELL MICROVASCULAR BARRIERS The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain bather functionality. Such polypeptides are refer... | 11/10/2011 |
| 20110268690 | POLYMERS CONTAINING POLY(HYDROXYALKANOATES) AND AGENTS FOR USE WITH MEDICAL ARTICLES AND METHODS OF FABRICATING THE SAME Compositions comprising poly(hydroxyalkanoates) and agents for use with medical articles are described.... | 11/03/2011 |
| 20110256186 | BIOMATERIAL BASED ON WHARTON'S JELLY FROM THE HUMAN UMBILICAL CORD The present invention relates to a biomaterial, specifically a hydrogel, formed from the extracellular matrix of the umbilical cord for its application in regenerative medicine. The invention particularly relates to a biomaterial made up of glycosaminoglycans isolated e... | 10/20/2011 |
| 20110256203 | POROUS CERAMIC SCAFFOLD HAVING AN ORGANIC/INORGANIC HYBRID COATING LAYER CONTAINING BIOACTIVE FACTOR AND METHOD THEREOF A method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid composite coating layer containing a bioactive factor is disclosed. The method includes; forming a porous ceramic scaffold, mixing a silica xerogel and a physiologically active organ... | 10/20/2011 |
| 20110237504 | DELIVERY AGENTS FOR ENHANCING MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS A delivery agent for delivering a biologically active agent to a warm-blooded animal includes a hydrophobic moiety covalently bonded to a hydrophilic moiety. The hydrophobic moiety can include bile acids, sterols, or hydrophobic small molecules. The hydrophilic moiety c... | 09/29/2011 |
| 20110236474 | Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatt... | 09/29/2011 |
| 20110223229 | IMMOBILISED BIOLOGICAL ENTITIES There is described inter alia a medical device having a surface which comprises a coating layer, said coating layer being a biocompatible composition comprising an anti-coagulant entity capable of interacting with mammalian blood to prevent coagulation or thrombus forma... | 09/15/2011 |
| 20110217339 | MUCOACTIVE AGENTS FOR TREATING A PULMONARY DISEASE The present invention relates to pharmaceutical compositions which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to ... | 09/08/2011 |
| 20110217249 | Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds The present invention provides compositions containing one or more antimicrobial peptide sequestering compounds and methods for topical application of such compositions to the skin to treat skin diseases and disorders such as rosacea in humans.... | 09/08/2011 |
| 20110212181 | COMPOSITIONS AND METHODS FOR TREATING CHRONIC RESPIRATORY INFLAMMATION Neutrophil elastase (NE) is a protease secreted by neutrophils during inflammation. Aberrant expression of NE such as in chronic respiratory inflammatory diseases, results in tissue destruction and decline in lung function. Compositions including an NE-targeting agent t... | 09/01/2011 |
| 20110212915 | MIXTURES OF POLYSACCHARIDES DERIVED FROM HEPARIN, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them.... | 09/01/2011 |
| 20110206667 | POLYMORPHISM IN THE APO(A) GENE PREDICT RESPONSIVENESS TO ACETYLSALICYLIC ACID TREATMENT This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.... | 08/25/2011 |
| 20110201573 | MIXTURES OF POLYSACCHARIDES DERIVED FROM HEPARIN, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them.... | 08/18/2011 |
| 20110200673 | OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN INHIBITING ANGIOGENESIS The present invention relates to a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 4,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. The present invention also relates... | 08/18/2011 |
| 20110200556 | CHEMOPREVENTION OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS Disclosed is a method for preventing the development of head and neck squamous cell carcinoma (HNSCC) in a mammal who is at risk for developing such carcinoma comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor to the mammal.... | 08/18/2011 |
